Oligodendrocytes are essential for the development, function, and health of the vertebrate central nervous system. These cells maintain axon myelination to ensure saltatory propagation of action potentials. Oligodendrocyte develops from neural progenitor cells, in a step-wise process that involves oligodendrocyte precursor specification, proliferation, and differentiation. The lineage progression requires coordination of transcriptional and epigenetic circuits to mediate the stage-specific intricacies of oligodendrocyte development. Epigenetic mechanisms involve DNA methylation, histone modifications, ATP-dependent chromatin remodeling, and non-coding RNA modulation that regulate the chromatin state over regulatory genes, which must be expressed or repressed to establish oligodendrocyte identity and lineage progression. In this review, we will focus on epigenetic programming associated with histone modification enzymes, chromatin remodeling, and noncoding RNAs that regulate oligodendrocyte lineage progression, and discuss how these mechanisms might be harnessed to induce myelin repair for treatment of demyelinating diseases such as multiple sclerosis.
Introduction
Oligodendrocytes (OLs) are a type of glial cell whose main function in the central nervous system (CNS) is to myelinate axons, ensuring the promotion of rapid, energy-efficient action potential propagation. A failure in myelin repair after OL damage contributes to the persistence of demyelination in debilitating diseases such as multiple sclerosis (MS) and leukodystrophies (Franklin and Gallo 2014) . OLs differentiate from OL precursor cells (OPCs) that arise from multipotent neural progenitor cells (NPCs). The transition from NPCs to primitive OPCs (uncommitted OPCs, which are Olig1/2 + /PDGFRa − ), to committed OPCs (e.g., PDGFRa + /NG2 + ), to mature OLs requires a series of complex changes involving an intricate network of interactions among transcription factors and epigenetic mechanisms (Emery and Lu 2015; Zuchero and Barres 2013) . Epigenetic mechanisms alter gene expression without actual changes in DNA sequence and induce subtle yet impactful regulatory influences. Epigenetic mechanisms involve histone modifications and variants, DNA methylation, ATP-dependent chromatin remodeling, and non-coding RNAs (Allis and Jenuwein 2016) .
Recent studies have revealed that epigenetic regulation is critical for OPC formation, maturation, and myelination. This knowledge should guide development of strategies to foster efficient remyelination to treat demyelinating diseases such as MS and leukodystrophies. Additionally, the understanding of myelination and remyelination may have an impact on human health that extends beyond these diseases per se to regeneration. Neuronal function cannot be fully restored until regrown axons have been properly myelinated. Accordingly, visual function was restored in mice only after regrown retinal axons had been myelinated (Bei et al. 2016) .
Chromatin remodeling is mainly mediated by histone modifying enzymes and ATP-dependent chromatin remodeling complexes. The histone-modifying enzymes modify the N-terminal tails of histone proteins, thereby changing chromatin structure or providing docking sites for the recruitment of specific proteins or enzymes that carry out chromatin remodeling or transcriptional regulation. Histone modifications occur on specific amino acids in histone tails and include acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, and ADP-ribosylation (Kouzarides 2007) . Of these modifications, histone acetylation has been shown to regulate OL lineage progression (Marin-Husstege et al. 2002; Shen et al. 2005; Ye et al. 2009; Zhang et al. 2016) . Histone acetylation states can be regulated by histone acetyltransferases (HATs; "writers") (Marmorstein and Zhou 2014) , and histone deacetylases (HDACs), the "erasers"). Histone acetylation state is recognized by bromo-, PHD-, Tudor-, and WD40-domains containing proteins (Chiang 2014; Gacias et al. 2014; Yun et al. 2011 ). There are four classes of HDACs in mammals, assigned based on their similarity to their yeast homologs and other factors: class I contains HDAC1, -2, -3, and -8; class II contains HDAC4, -5, -6, -7, -9, and -10; class III contains SIRTs 1-7, also called Sirtuins, which are NAD-dependent; and class IV contains only HDAC11 (Glaser 2007; Thiagalingam et al. 2003) . ATPdependent chromatin remodelers use energy from ATP hydrolysis to unwrap or disrupt association between DNA and histones, slide/reposition nucleosomes along DNA, exchange one histone variant for another, or to evict nucleosomes from DNA (Allis and Jenuwein 2016; Xu et al. 2013) . This review provides an overview of recent studies of chromatin remodeling and epigenetic mechanisms that regulate OL lineage progression and myelination in the CNS, particularly focusing on roles of histone modifications, ATP-dependent chromatin remodeling, and non-coding RNAs.
Histone modifying enzymes in oligodendrocyte development

Class I HDACs in oligodendrocyte lineage development
A series of studies have utilized different HDAC inhibitors to elucidate the role of HDACs in OPC specification and differentiation (Hsieh et al. 2004; Lyssiotis et al. 2007; Marin-Husstege et al. 2002) . The treatment of NPCs with the HDAC class I inhibitor valproic acid (VPA) inhibits the specification of OPCs from NPCs and enhances specification toward neuronal differentiation, likely due at least in part to the effect of HDACs on the neurogenic transcription factor NeuroD (Hsieh et al. 2004) . Although VPA inhibits myelination when used early in OL development, it does not have an effect when utilized after the onset of myelination (Shen et al. 2005) , suggesting a stage-dependent switch in HDAC regulation. HDAC inhibitors trichostatin A (TSA) and sodium butyrate decrease differentiation of OPCs and disinhibit expression of Id2, Egr1, and Sox11 in rats and ID4 and SOX2 in humans (Conway et al. 2012; Swiss et al. 2011) , suggesting a role of class I HDACs in promoting OPC differentiation.
HDAC1 is vital for OPC specification in zebrafish through the promotion of Olig2 expression and downregulation of Nkx2.2 expression (Cunliffe and Casaccia-Bonnefil 2006) . Simultaneous genetic ablation of both HDAC1 and HDAC2, but not of the single genes alone, in OL lineage cells inhibits OPC proliferation and subsequent differentiation in the murine CNS, suggesting functional redundancy of HDAC1/2 in mammalian OPC development ). HDAC1, along with HDAC3 and HDAC10, deacetylates the transcription factor Olig1 to promote OL differentiation (Dai et al. 2015) , suggesting a non-histonedependent effect of HDACs in OL development. Intriguingly, in neural stem cells (NSCs), ablation of HDAC2 in conjunction with thyroid hormone triiodothyronine (T3) treatment increases expression of OL lineage genes through derepression of Sox8 and Sox10 expression, factors that promote the OL lineage (Castelo-Branco et al. 2014a) , suggesting a stage-dependent function of HDACs in specification vs. differentiation in OL lineage development. Additionally, HDAC activity can be regulated by extrinsic signaling cues. Induction of sonic hedgehog signaling in OPCs promotes differentiation at least in part through HDAC1 and HDAC2, whereas treatment with bone morphogenetic protein 4 decreases HDAC activity and thus hinders differentiation (Wu et al. 2012) .
HDAC1 and HDAC2 both work with corepressors and form repressive complexes such as the Sin3, nucleosome remodeling and deacetylating (NuRD), and Co-REST complexes (de Ruijter et al. 2003) . HDACs are also often recruited and interact with transcription factors to target specific genes. The transcription factor YY1 recruits HDAC1 to the promoter regions of inhibitory genes such as Id4 to repress their expression during OL differentiation (He et al. 2007 ). In addition, the HDAC1/2 repressor complex can compete with β-catenin to interact with TCF7L2 (also known as TCF4), a member of the TCF transcription factor family ). When interacting with β-catenin, TCF7L2 serves as a repressor of OL differentiation, but TCF7L2 in conjunction with HDAC1/2 allows OL differentiation to occur ). In mice, the chemotherapy drug 5-fluorouracil causes CNS demyelination via its interaction with TCF7L2 and consequent inhibition of the HDAC1/2-TCF7L2 interaction (Weng et al. 2014) .
In NSC culture, HDAC3, another class I HDAC, represses neuronal specification, thus promoting the OL lineage development (CasteloBranco et al. 2014a) . Whereas HDAC1/2-deficient OPCs do not adopt astrocytic fates, Hdac3 deletion in the Olig1-expressing primitive OPCs (pri-OPC) leads to an increase in astrocytes with a concomitant loss of OL lineage cells, suggesting that HDAC3 functions as a molecular switch for OL and astrocyte lineage determination in the developing brain. In addition, HDAC3 appears to cooperate with acetyltransferase EP300 (also known as p300) to promote Olig2 expression and thereby prime and maintain OPC identity while inhibiting NFIA and Stat3-mediated astrogliogenesis (Zhang et al. 2016) . While the roles of HDAC3 and p300 may seem conflicting, coordination between HDAC3 and p300 appears to exert activating effects with net HAT activity to initiate the transcriptional program for OPC specification (Zhang et al. 2016) . In addition, HDACs may positively regulate gene transcription (Greer et al. 2015) . Intriguingly, the deletion of DAD domains of both NCoR1 and SMRT in mice, which results in a lack of histone deacetylase activity in the NCoR/HDAC3 complex (You et al. 2013) , does not lead to an oligodendrocyte-astrocyte fate switch and dysmyelination (Zhang et al. 2016) . This suggests that HDAC3 activity is independent of NCoR1/SMRT-mediated histone deacetylation in oligodendrogenesis and that HDAC3 activity per se or HDAC3/NCoR-mediated transcriptional regulation or modification of non-histone substrates controls oligodendrocyte-astrocyte fate switching (Zhang et al. 2016) .
Class II and class IV HDACs in oligodendrocyte lineage progression. Class II HDACs only exhibit deacetylation function when recruited with class I HDACs and in complex with the SMRT/NCoR co-repressor (Fischle et al. 2000) . Although both class I and class II HDACs function during tissue development, class I HDACs appear more important during brain development than are class II HDACs ). It has been reported that HDAC6 is present in rat brain OLs, where it downregulates the acetylation of Tau (Noack et al. 2014 ), a microtubule-associated protein that is necessary for the transport of MBP mRNA in OLs, suggesting that HDAC6 may have a role in OL maturation and myelination (Richter-Landsberg 2016).
HDAC11 is found in both dentate gyrus granule neurons and mature OLs (Liu et al. 2008) . During OL maturation in rats, HDAC11 deacetylates lysine 9 and lysine 14 of histone 3 (H3) bound to PLP and MBP myelin genes (Douvaras et al. 2016; Liu et al. 2009 ). Intriguingly, mechanical strain on OLs can increase levels of HDAC11 and promote OL differentiation (Jagielska et al. 2017) . The specific role of class II HDACs and HDAC11 in CNS myelination in vivo requires further investigation.
Class III SIRTs in oligodendrocyte precursor cell differentiation. SIRTs, class III HDACs that deacetylate K16 of histone 4, also play important roles in OL lineage development (Vaquero et al. 2007 ). In OPC specification, SIRT1 and SIRT2 have redundant functions involving nicotinamide phosphoribosyltransferase, a mammalian enzyme that catalyzes the synthesis of NAD + (Stein and Imai 2014) . SIRT2 has been shown to deacetylate both histones and α-tubulin and to interact with HDAC6 in the myelin proteome (North et al. 2003; Roth et al. 2005) . As OPCs differentiate into OLs, there is an increase of SIRT2 and α-tubulin acetylation ). SIRT2 may reduce α-tubulin acetylation in OLs and thus impede differentiation Tang and Chua 2008) . In contrast, SIRT2 can also promote differentiation of CG4 oligodendroglial cells (Ji et al. 2011) . Such conflicting roles of SIRT2 in OL differentiation should be studied further in a spatiotemporally specific manner to determine the precise mechanism through which SIRT2 regulates OL development and myelination. SIRT2 mRNA is stabilized by the RNA-binding protein Quaking, and this stabilization promotes OL differentiation due to the sustained levels of SIRT2 (Thangaraj et al. 2017 ). The precise role of SIRT2 in oligodendroglial lineage differentiation and myelin maintenance remains to be defined.
Histone acetyltransferases in oligodendrocyte lineage progression
The roles of specific histone acetyltransferases (HATs) in OL development have yet to be fully elucidated. Loss-of-function mutations in the EP300 gene encoding the HAT p300 cause Rubinstein-Taybi syndrome resulting in hypoplasia of the corpus callosum, congenital hypomyelination, and other systemic abnormalities (Lee et al. 2015; Solomon et al. 2015) . EP300 has been shown to interact with HDAC3 to promote Olig2 expression to regulate oligodendrocyte-astrocyte fate switching (Zhang et al. 2016 ). This raises the possibility that enhancing HAT activity, such as activity of EP300, might promote oligodendrogenesis and regeneration. Another EP300-related acetyltransferase, CBP, which is a CREB-binding protein, acetylates Olig1 promoting OL differentiation due to an increase in Olig1 retention in the cytoplasm (Dai et al. 2015) . Although the role of HATs in the OL lineage progression is not completely understood, coordination of HAT with HDAC activity suggests that HATs may serve as vital regulators in OL development and myelin regeneration through reactivating OPC differentiation programs after injury (Fig. 1). 
Other histone modifications in oligodendrocyte development and myelination
One mediator of histone methylation is the polycomb repressive complex 2 (PRC2), containing histone methyltransferase activity (Rajasekhar and Begemann 2007) . PRC2 contains EZH2, the catalytic subunit of the PRC, which catalyzes the trimethylation of lysine 27 of H3 (Kim and Roberts 2016) . Overexpression of EZH2 in NSCs increases OL frequency through OPC expansion and a reduction in astrocytes in vitro (Sher et al. 2008) . The opposite occurs when EZH2 is silenced, suggesting that EZH2 promotes OL proliferation. In addition, selective ablation of the EZH2 floxed allele in OL lineage cells in the developing CNS causes a reduction in CC1 + and MBP + OLs and an increase in the OPC fraction within the OL lineage , suggesting that EZH2 regulates OPC proliferation and differentiation processes. Notably, formation of gliomas or diffuse intrinsic pontine glioma (DIPG) has been attributed to loss-of-function mutations in PRC2 and H3K27me3 Lewis et al. 2013) . Although histone demethylases have not been associated specifically with OL development, overexpression of histone demethylase JMJD3, which contains a jumonji-C domain and removes trimethylation on H3K27 (Xiang et al. 2007) , induces neuronal gene expression in NSCs (Jepsen et al. 2007 ). Other histone methylation modifications are also pertinent, including H3K9 methylation. During OL differentiation, the level of H3K9 trimethylation increases (Liu et al. 2015) . The lysinespecific demethylase LSD1, which demethylates H3K4 and H3K9, interacts with the nuclear receptor TLX to promote NSC proliferation (Sun et al. 2010) . Recently, the transcription factor Myt1 was identified as a subunit of the LSD1 complex (Yokoyama et al. 2014 ). Inhibition of either Myt1 or LSD1 expression reduces demethylation of H3K4 without affecting the H3K9 methylation state. Deficiency in either Myt1 or LSD1 also derepresses expression of a number of genes, including PTEN, Fig. 1 . Chromatin modifications regulate chromatin structure to control oligodendrocyte lineage progression. The acetylation of histone tails by histone acetyltransferases (HATs) establishes a more relaxed state in the chromatin that results in transcriptional activation (activated state). Histone deacetylation by HDACs reverses the activating chromatin state to a "poised" or "inactive" chromatin state to inhibit gene transcription. Histone K27 trimethylation mediated by histone methyltransferases (HMTs) e.g. the PRC2 complex, can lead to chromatin compaction and transcriptional repression (repressive state), this process can be reversed by histone demethylases (HDMs) to form a "poised" chromatin state, which is transcriptionally silent. Another group of chromatin remodelers depends on ATP to change the chromatin structure for activating gene expression. The SWI/SNF family includes complexes with these ATPase subunits, such as Brg1 that regulates OPC specification from NSCs and OPC differentiation from pri-OPC progenitors. CHD family is another family of ATP-dependent chromatin remodelers. CHD7 interacts with Sox10 to regulate the timing of OL differentiation via the activation of genes like Myrf and Olig1 in the central nervous system. E. Koreman et al. Molecular and Cellular Neuroscience 87 (2018) 18-26 which inhibits myelination, and inhibits cell proliferation of a neuroblastoma cell line (Yokoyama et al. 2014 ). In addition to lysine methylation, arginine can also be methylated post-translationally (Bedford 2007) . The arginine methyltransferase PRMT1 appears to be crucial to the OL maturation process. Mice lacking PRMT1 develop severe hypomyelination (Hashimoto et al. 2016 ). In addition, another arginine methyltransferase, PRMT5, interacts with the transcription factor SC1 (also known as PRDM4) to maintain NSCs in a "stem-like" state (Chittka et al. 2012) .
Another post-transcriptional modification is histone ubiquitination (Cao and Yan 2012) . The RING finger domain protein Ring1B is a component of PRC1 that facilitates monoubiquitylation of histone 2A at K119 (Leeb and Wutz 2007) . Ring1B is vital for NSC proliferation and self-renewal (Román-Trufero et al. 2009 ).
Crosstalk among histone modifying enzymes coordinates cell growth and differentiation processes. During neuronal differentiation, arginine methyltransferase PRMT6 interacts with subunits of PRC1 and PRC2 to inhibit the expression of HOXA genes (Stein et al. 2016 ). Another example of crosstalk involves the NuRD complex, which includes the ATP-dependent chromatin remodeler Chd4 and HDAC1/2. NuRD and PRC2 both bind to the promoters of a set of genes important for OL development (Hung et al. 2012; Reynolds et al. 2012) . These interactions between different histone modifying enzymes suggest the presence of a more complex system of epigenetic modification. As research tools and techniques continue to improve, more examples of crosstalk will be elucidated, aiding in the formation of a more detailed map of epigenetic regulation of OL development.
Histone modifications and CNS remyelination
HDACs are also necessary for remyelination after injury. In the CNS, seven days after a stroke, there is an increase in OPC proliferation and differentiation as well as an increase in HDACs 1, 2, and 4 in OPCs (Kassis et al. 2014) . Under these conditions in differentiating OLs, there is an increase of HDAC2, but a decrease of HDAC1, although injury cells may be less synchronized in their stage of lineage progression.
HDAC inhibitors have potential in remyelination therapies. Immediately after a permanent middle cerebral artery occlusion, treatment with pan-HDAC inhibitors sodium butyrate and TSA appeared to protect against the loss of OPCs and OLs (Kim and Chuang 2014) . Even delayed treatment with the HDAC inhibitor VPA after middle cerebral artery occlusion increases OL differentiation and survival (Liu et al. 2012) . Treatment with class I and II HDAC inhibitor scriptaid improved the recovery process after a traumatic brain injury via promotion of microglia/macrophages to the beneficial M2 phenotype (Wang et al. 2015) . Although treatment using HDAC inhibitors enhances remyelination in the above experimental paradigms, social isolation through neonatal maternal separation in rats has been shown to yield hypomyelination through decreased HDAC1/2 levels and increased Wnt signaling . In contrast, mice raised in an enriched environment have a large increase in HDAC1/2 levels and reduced Wnt signaling, thus promoting remyelination (Zheng et al. 2017) . The function of HDAC3 in CNS remyelination remains to be further defined. Present studies indicate stage-(neonatal vs. adulthood), context-specific functions of class I HDACs in OL myelination and remyelination.
Mechanisms involving the class III HDAC SIRT1 and NAD + replenishment are also critical for neuroprotection against ischemic stroke (Della-Morte et al. 2009; Hernández-Jiménez et al. 2013; Wang et al. 2011; Wang et al. 2008; Ying et al. 2007 ). SIRT1 deacetylates retinoblastoma protein (Rb), which causes E2F1 dissociation from the Rb/E2F1 complex and promotes OPC proliferation after hypoxia injury (Jablonska et al. 2016) . Intriguingly, at least partially through the activation of p38 MAPK and AKT pathways, inactivation of SIRT1 in NSCs promotes OPC proliferation and in turn improves remyelination in animal models of demyelinating injury including lysolecithin-induced demyelination and during chronic experimental autoimmune encephalomyelitis (EAE) (Rafalski et al. 2013 ). These opposing effects of SIRT1 indicate a context-dependent complexity of epigenetic mechanisms in OPC proliferation after injury. Although in some cases HDAC inhibitors may be beneficial, the diverse interactions involving HDACs means that their inhibition can sometimes cause detrimental effects. For example, the FDA-approved HDAC inhibitor, suberoylanilide hydroxamic acid can cause a decrease in mouse cortical OPC survival and could thus pose a risk to human patients (Dincman et al. 2016 ). Due to the intricate, distinct and nuanced functions of individual HDAC family members, such complications call for careful interpretation of study outcomes that employ pan-HDAC inhibitors. More research into potential cell-and targetspecific therapeutic approaches is also needed. Although histone acetylation has been shown to regulate OL lineage progression and remyelination, the role of other histone modifications such as methylation, phosphorylation, and sumoylation and how these modifications coordinate with one another in the regulation of OL remyelination are yet to be fully defined.
Histone modifications in multiple sclerosis
In MS, histone deacetylation can occur early in disease progression; however, as the disease develops, histone deacetylation declines as evidenced by an increase in histone acetylation in the white matter from the frontal lobe of MS patients in the later stages of the disease (Pedre et al. 2011) , although the cell types or levels of histone acetylation remain to be defined. HDAC inhibition and the thyroid hormone triiodothyronine (T3) can synergize to elevate terminal OL differentiation in the CNS (Castelo-Branco et al. 2014b) . Treatment in rats with VPA and l-thyroxine, the precursor to thyroid hormone T3, at the onset of EAE, attenuated encephalitogenic CD4 + T cells, and resulted in an improvement in clinical symptoms, increased expression of myelinrelated genes, and prevented the spread of inflammatory demyelination to the brain (Castelo-Branco et al. 2014b ). The HDAC inhibitor TSA has also been shown to improve EAE clinical symptoms (Camelo et al. 2005 ). These observations suggest that combined acute treatment with HDAC inhibition and T3 have potential in treatment of MS by targeting inflammation and improving remyelination. Treatment with resveratrol (SRT501), which activates SIRT1, prevents neuronal damage and long-term neurologic dysfunction in EAE (Shindler et al. 2010; Shindler et al. 2007 ). In addition, overexpression of SIRT1 in neurons in EAE mice ameliorates symptoms associated with EAE and reduce CNS demyelination and inflammation (Nimmagadda et al. 2013) , suggesting a neuroprotective effect of SIRT1 through both immunomodulatory and neuroprotective mechanisms.
Recently, it has been shown that histone methylation related to mitochondrial changes is associated with MS (Singhal et al. 2015) . Decreases in the methyl donor betaine were correlated with reduced levels of histone H3 trimethylation (H3K4me3) in NeuN + neuronal nuclei in the MS cortex, which may downregulate expression of metabolic genes in neurons (Singhal et al. 2015) . Thus, methionine metabolism and methylation may be linked to abnormal neuronal metabolisms and neurodegeneration in MS (Singhal et al. 2015; Webb and Guerau-de-Arellano 2017) .
ATP-dependent remodelers in the oligodendrocyte lineage progression and myelination
ATP-dependent chromatin remodelers use ATP to loosen nucleosomes and induce dissociation of DNA from histones. These remodeler complexes can be classified into four families that depend on their catalytic ATPase subunit: the SWI/SNF family includes ATPase subunits Brahma (BRM; also known as Smarca2) and Brahma-related 1 (Brg1; also known as Smarca4); the INO80 family includes ATPase subunits INO80, SRCAP, and P400; the ISWI family includes ATPase subunits SNF2L and SNF2H; and the CHD family includes the ATPase subunits CHD1-9 (de la Serna et al. 2006; Runge et al. 2016) .
OPCs can be reprogrammed to a more developmentally plastic state called a multipotent neural stem-like cell (NSLC) (Kondo and Raff 2000) . This reprogramming is mediated in part through the recruitment of the chromatin-remodeler BRM of the SWI/SNF family to the Sox2 promoter to promote Sox2 expression (Kondo and Raff 2004) . This suggests a possible function of ATP-dependent remodelers in OPC specification.
Another member of the SWI/SNF family, Brg1 has been shown to be vital for oligodendroglial fate specification from murine NSCs. Brg1 is the helicase component of the mammalian SWI/SNF-related chromatin remodeling complex. In NSCs, Brg1 interacts with the Olig2 promoter to regulate Olig2 expression during early development (Matsumoto et al. 2016; Matsumoto et al. 2006) . In contrast, after induction of differentiation in cultured rat OPCs by transient T3 treatment, the Brg1 gene locus is substantially occupied by RNA polymerase II for activating Brg1 transcription at the onset of differentiation. Brg1 is further transcriptionally pre-patterned and recruited by the pioneer transcription factor Olig2 in the OL lineage to achieve the target binding specificity, and activates expression of OL-differentiation-associated genes. The reciprocal regulation of Olig2 by Brg1 in NSCs suggests a potential positive feedback loop for Olig2 to interact with and recruit Brg1 to promote OL lineage progression. Deletion of Brg1 at the pri-OPC stage in mice directed by Olig1-Cre results in a dysmyelinating phenotype with severe defects in the formation of mature OLs ).
Deletion of Brg1 in committed or postmitotic OPCs by CNP-Cre or NG2-Cre results in a decrease in frequency of myelinating differentiated OLs, while Brg1 regulates pro-differentiation factor Sox10 expression during or immediately after OPC specification (Bischof et al. 2015; Yu et al. 2013) . The discrepancy of Brg1 functions in OPC differentiation might be due to the difference in the OPC state between in vitro and in vivo conditions, the distinct states of OPCs (pri-OPC, proliferative or postmitotic OPC), or different recombination efficiency of Cre lines during the transition of OPC to differentiated OLs in distinct CNS regions. Further studies should be carried out by using region-and stage-specific Cre lines. Deletion of Brg1 in PDGFRa + OPCs in vivo leads to their differentiation defects (Koreman and Lu, unpublished data) , suggesting that Brg1 is required for OPC differentiation. Thus, these studies indicate a stage-dependent Brg1 function in OL lineage progression. Brg1 is essential for NSC specification into OPCs and for the transition of Olig1 + pri-OPCs into differentiated OLs, but is only partially required for differentiation of CNP + or NG2 + committed OPCs into mature OLs during OL lineage progression (Fig. 1 ). Brg1 and Olig2 target distinct subsets of genes during early and late phases of differentiation to control OL lineage progression. The gene encoding chromatin remodeler CHD7, is a target of Brg1 and Olig2 in the differentiating phase of OL development. CHD7 targets the enhancers of Myrf and Olig1 and promotes their expression to induce OL maturation ). CHD7 and Brg1 target different genes pertaining to OL differentiation , suggesting that each chromatin remodeler has distinct targets at different stages during OL Fig. 2 . Non-coding RNAs stage-specifically regulate oligodendrocyte development and myelination. Non-coding RNAs including miRNAs and lncRNAs play an important role in oligodendrocyte development, myelination and remyelination. For instance, miRNAs transcribed from the miR-17-92 cluster promote OPC proliferation, whereas miR-219, miR-338, and miR-23 repress expression of genes associated with the inhibition of OL differentiation. lncRNAs)can regulate OL lineage progression by associating with remodeling complexes like PRC2. lncRNAs like Sox8OT interact with and regulate the activity of differentiation factors such as Sox8 and function as OL differentiation modulators. Moreover, miRNAs can sometimes regulate lncRNAs, such as the case of miR-23 in the promotion of the lncRNA 2700046G09Rik expression in OL differentiation.
E. Koreman et al. Molecular and Cellular Neuroscience 87 (2018) 18-26 lineage progression (Fig. 1) . At present, the roles of other ATP-dependent chromatin remodelers in OL lineage development have not been elucidated.
Noncoding RNAs and chromatin remodeling in myelination
4.1. microRNA-mediated chromatin remodeling microRNAs (abbreviated miRNAs; small noncoding RNAs with~22 nucleotides) are important epigenetic regulators of gene expression. miRNAs hybridize to 3′-untranslated regions and the coding regions of mRNAs to cause degradation of the mRNAs or to inhibit their translation (Bartel 2004; Chekulaeva and Filipowicz 2009) . This translational regulation is related to association between the miRNA-containing RNA-induced silencing complex and transcription factors and chromatin-modifying complexes (Schwartz et al. 2008; Vasudevan et al. 2007) .
Deletion of gene encoding the miRNA processing enzyme Dicer1 revealed that miRNAs are critical for OL differentiation, myelination, and myelin maintenance (Dugas et al. 2010; Shin et al. 2009; Zhao et al. 2010) . miRNAs miR-219 and miR-338 are abundant in differentiated OLs (Dugas et al. 2010; Lau et al. 2008; Zhao et al. 2010) . These miRNAs target OL differentiation inhibitors, including PDGFRα, Hes5, and Sox6, to promote OL differentiation (Dugas et al. 2010; Zhao et al. 2010) . miR-219 is both necessary and sufficient to promote OL differentiation (Dugas et al. 2010; Wang et al. 2017; Zhao et al. 2010) . Moreover, miR-219 cooperates with miR-338 to regulate OL maturation and the full extent of CNS myelination . Affinity pulldown assays indicated that miR-219 associates targets mRNAs encoding differentiation inhibitors, such as Lingo1 and Etv5, to promote OL differentiation in a stage-specific manner (Fig. 2) .
miR-219 treatment promotes remyelination and functional recovery in animal models of MS including lysolecithin-induced demyelination and EAE . miR-219 also enhances remyelination in cuprizone-induced demyelination by promoting expression of monocarboxylate transporter MCT1 (Liu et al. 2017a ). In addition, transplantation of miR-219-overexpressing OPCs promotes remyelination and improves functional recovery in a cuprizone-induced chronic demyelination model (Fan et al. 2017) , suggesting that miR-219 has potential for use as an MS therapy.
Another important miRNA for remyelination is miR-146a, which was shown to promote OL differentiation and facilitate the remyelination after demyelinating injury and stroke (Liu et al. 2017b; Zhang et al. 2017) . In addition to regulating OL differentiation and maturation, miRNAs also regulate OPC proliferation. The human oncomir miR-17-92 cluster encodes six miRNAs: miR-17, miR18a, miR-19a, miR-19b-1, miR-20a, and miR-92-1 (Mendell 2008) . Knockout of the miR-17-92 cluster in mice decreased the number of OLs (Budde et al. 2010) , suggesting that this miRNA cluster regulates the proliferation of OPCs. Conversely, miR-19b expression promotes OPC proliferation by activating AKT signaling and inactivating PTEN (Budde et al. 2010) . Also, miR-297c-5p, a member of the Sfmbt2 cluster, was found to inhibit OPC proliferation while promoting OL maturation (Inoue et al. 2017; Kuypers et al. 2016) .
miRNAs can regulate gene expression by targeting chromatin modifiers. miR-23 downregulates expression of LMNB1 to promote OL maturation and maintain myelin integrity (Lin and Fu 2009) . LMNB1 represses OL maturation and inhibits expression of myelin proteins such as MBP, proteolipid protein PLP, and myelin oligodendrocyte glycoprotein MOG. Mutations in LMNB1 can cause severe diseases related to loss of myelin such as leukodystrophy (Lin and Fu 2009) . Furthermore, miR-23a positively regulates myelin gene expression by targeting PTEN and a long non-coding RNA (lncRNA) 2700046G09Rik, while downregulating neuronal gene expression .
miRNAs such as miRNA-9 and miR-124a can repress expression of BAF53a, a component of SWI/SNF chromatin remodeling complexes, leading to the inhibition of neural progenitor proliferation (Yoo et al. 2009 ). Expression of these two miRNAs is repressed by the transcriptional repressor REST (also known as NRSF), an inhibitor of neuronal differentiation (Yoo et al. 2009 ). This mechanism shows that RESTmediated repression of miRNAs directs the activity of BAF chromatin remodeling complexes in neurogenesis.
Long non-coding RNAs mediated chromatin remodeling in oligodendrocyte differentiation.
lncRNAs are RNA transcripts longer than 200 nucleotides that serve a very similar function to miRNAs. lncRNAs can fold into complex structures that allow them a greater scope of functions than those of miRNAs (Fatica and Bozzoni 2014) . lncRNAs mediate epigenetic changes through cis-and trans-acting mechanisms including recruitment of chromatin remodeling complexes to specific genomic loci (Dinger et al., 2008; Khalil et al. 2009; Redrup et al. 2009 ). For example, the chromatin remodeler PRC2 is regulated by many lncRNAs including HOTAIR, ANRIL, and lncOL1. HOTAIR, transcribed from the HOXC locus, recruits PRC2 and silences transcription of the HOXD locus in trans (Rinn et al. 2007 ). Additionally, ANRIL interacts with PRC2 and PRC1 to form heterochromatin surrounding the INK4b-ARF-INK4a locus regulating expression of these genes in cis (Aguilo et al. 2011) .
In recent studies analyzing the expression of lncRNAs throughout OL progression, a series of lncRNAs were identified that are enriched in OPCs and OLs (Dong et al. 2015; He et al. 2017; Mercer et al. 2010) . A conserved chromatin-associated lncRNA, lncOL1, is restricted to OLs . Overexpression of lncOL1 promotes precocious OL differentiation in developing cortex, whereas genetic inactivation of lncOL1 causes a delay in CNS myelination and remyelination. lncOL1 interacts with Suz12, a subunit of histone methylation modifier PRC2, to inhibit a differentiation inhibitory network that maintains the OPC state, leading to the promotion of OPC differentiation ). Thus, lncOL1 forms an epigenetic circuitry through interaction with chromatin-modifying complexes to control the myelination process in the CNS (Fig. 2) . PRC2 is physically associated with a subset of lncRNAs, either alone or together with other chromatin remodeling complexes such as CoREST and SMCX (Khalil et al. 2009 ). Levels of an OPC-enriched lncRNA, lnc-OPC, are increased during OPC specification and in glial progenitors from EAE (Dong et al. 2015) . Lossof-function analysis indicates that lnc-OPC is regulated by Olig2 and is critical for OPC genesis (Dong et al. 2015) (Fig. 2) .
Another long noncoding RNA possibly involved in the OL lineage is called Sox8OT, and abbreviation for Sox 8 Opposite Transcript (Mercer et al. 2010) . Upregulation of Sox8OT in OPCs increases expression of Sox8 mRNA, which encodes an OL pro-differentiation factor (Stolt et al. 2005) . This suggests simultaneous bidirectional expression of Sox8 and Sox8OT. Functions of OL lineage-expressing lncRNAs including Sox8OT in OL myelination have yet to be discovered.
Conclusion and perspectives
Epigenetic mechanisms, including chromatin remodeling and regulation mediated by non-coding RNAs, have vital roles in OL lineage development and myelination. Epigenetic modifiers may interact or coordinate with stage-specific transcriptional regulators to regulate different pathways in a stage-dependent manner during OL differentiation and myelination. Recent experiments that have shed light on this interacting network expanded the already complex map of regulation in myelination. A growing understanding of the critical role of chromatin modifications in OL myelination and remyelination provides new opportunities to interrogate the biological consequences of the interplay between chromatin remodeling and cellular signaling pathways. Elucidation of the contributions of causal versus stochastic epigenetic modifications will require single-cell transcriptome profiling to quantitatively measure the transcriptional outputs at high resolution.
Given that many of the chromatin modifiers are enzymes, these factors could potentially be targeted to promote myelin repair after injury. Fully understanding the epigenetic mechanisms in myelination and remyelination will facilitate the identification of drug targets for myelin repair. For instance, HDAC inhibition exhibits a cellular contextand stage-specific effect on OL myelination and remyelination and the diverse roles of HDACs means that inhibition may be detrimental under certain circumstances and beneficial in others. Our current understanding of epigenetic mechanisms involved in remyelination suggest that development of potent, selective, small molecule compounds that modify epigenetic enzyme activity to re-activate the myelinogenic program will result in treatments for those afflicted by demyelinating diseases such as MS.
